Innate Immunotherapeutics, together with a number of Australian, Canadian, and Danish scientific collaborators, has had multiple abstracts accepted for presentation at the American Academy of Neurology (AAN) Annual Meeting being held in Boston between 22nd and 28th of April. The data from this collective substantial body of work provides solid support for the proposed mechanism of action of MIS416, the Company's drug candidate currently in clinical trial for patients with non-relapsing secondary progressive multiple sclerosis (SPMS).
The AAN Annual Meeting is the world's largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to network, discuss cutting-edge research, and take part in top-rated education programmes across a wide variety of topics.
For further information please download PDF attached:
Download this document
